Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Geron Earnings: An Early Look

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Earnings season is winding down, with most companies already having reported their quarterly results. But there are still some companies left to report, and Geron (NASDAQ: GERN  ) is about to release its quarterly earnings. The key to making smart investment decisions with stocks releasing their quarterly reports is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you'll be less likely to make an uninformed knee-jerk reaction to news that turns out to be exactly the wrong move.

Geron is arguably best known not for what it did do but what it didn't do. Having originally been involved in stem-cell research, Geron decided to give up on the promising but controversial area. Let's take an early look at what's been happening with Geron over the past quarter and what we're likely to see in its quarterly report on Tuesday.

Stats on Geron

Analyst EPS Estimate


Year-Ago EPS


Revenue Estimate


Change From Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance.

What's been happening with Geron this quarter?
Analysts haven't changed their estimates on Geron one bit, given that the company has so little revenue coming in and has relatively predictable expenses. The stock has risen nearly 40% since early December, but that's been only a short respite from much longer-term declines over the years.

Geron drew a lot of attention when it decided in 2011 to stop its stem-cell research. Since then, it has struggled to find a buyer for its stem-cell assets, and in January, Geron finally accepted a deal in which tiny biotech BioTime (NYSEMKT: BTX  ) offered to contribute $35 million in cash and stock to a subsidiary in exchange for a 79% stake, leaving Geron shareholders with the other 21%. Given the challenges that StemCells (NASDAQ: STEM  ) has had in moving forward with stem-cell products, it's hard to fault Geron for giving up on the difficult area.

But Geron's attempts to move in other directions haven't been very successful. Back in September, the company cancelled a clinical trial looking at its imetelstat treatment for breast cancer, and it chose not to put the drug into a trial for treating non-small-cell lung cancer either. Moreover, in December, the company announced a failure with its GRN1005 prospect, which didn't produce the desired effect against brain metastases in breast-cancer patients.

In Geron's quarterly report, it needs to elaborate more on the successful data it reported back in December for imetelstat's impact on a blood disorder called essential thrombocythemia. Although the indication obviously isn't as high-status as breast cancer, it could still support what could become much greater revenue for Geron in the long run.

The best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Click here to add Geron to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 11, 2013, at 6:34 PM, 123spot wrote:

    Dan,do you know what happened to the SCI patients enrolled in Geron's original stem cell trials? I keep them in my thoughts, but can find nothing on status. Thanks. Spot

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2303419, ~/Articles/ArticleHandler.aspx, 9/30/2016 8:07:02 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,308.15 164.70 0.91%
S&P 500 2,168.27 17.14 0.80%
NASD 5,312.00 42.85 0.81%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/30/2016 4:00 PM
GERN $2.26 Up +0.06 +2.73%
Geron CAPS Rating: ***
BTX $3.90 Up +0.23 +6.27%
BioTime CAPS Rating: *
STEM $1.36 Down -0.01 -0.73%
StemCells CAPS Rating: *